CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM...
Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in...
View ArticleBiomarkers help resolve differential diagnosis between MPM and non-cancerous...
Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive...
View ArticlePenn researchers awarded $10 million grant to study adverse health effects,...
Researchers at the Center of Excellence in Environmental Toxicology, Perelman School of Medicine at the University of Pennsylvania, have been awarded a $10 million grant from the National Institute for...
View ArticleFAK inhibitors prevent ovarian cancer progression
A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report...
View ArticleEnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV...
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced...
View ArticlePenn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL...
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory...
View ArticleResearchers receive $8 million NCI grant to study effects of PDT in patients...
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer...
View ArticlePenn receives $8 million grant from NCI to study effects of PDT
Researchers at the Perelman School of Medicine at the University of Pennsylvania in collaboration with the Roswell Park Cancer Institute have received an $8 million grant from the National Cancer...
View ArticleConcordia subsidiary enrolls patients in Phase 2 trial to evaluate PDT with...
Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary...
View ArticleCD157 important in malignant pleural mesothelioma
CD157 plays a pivotal role in the progression of malignant pleural mesothelioma and may be useful in the stratification of patients into different prognostic groups, Italian research suggests.
View ArticleConcordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN
Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary,...
View ArticleResearchers suggest that proportion of IPF may be due to unknown exposure to...
A proportion of idiopathic pulmonary fibrosis cases may be linked with asbestos exposure, according to the results of a new study.
View ArticleEnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer...
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that,...
View ArticleCurcumin, cancer-inhibiting peptides show promise in slowing progression of...
A common Asian spice and cancer-hampering molecules show promise in slowing the progression of mesothelioma, a cancer of the lung's lining often linked to asbestos. Scientists from Case Western Reserve...
View ArticlePD-L1 protein could be a potential immunotherapy target for malignant pleural...
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data...
View ArticlePinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile...
Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there...
View ArticleConcordia Healthcare reports record revenues of 147% in third quarter 2014
Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today...
View ArticleCurcumin and tackling mesothelioma: an interview with Dr. Afshin Dowlati
An important point about this work is that the research into curcumin was conducted following a discovery about mesothelioma, rather than being the primary endpoint of the study.
View ArticleMedical experts to discuss Saatchi Bill at free public event
The Saatchi Bill claims that it will help doctors to innovate new treatments and cures, safely and responsibly, for cancer and other diseases.
View ArticleFL118 agent shows efficacy as personalized, targeted therapy for certain...
A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies...
View Article